Elizabeth A Cromwell
Overview
Explore the profile of Elizabeth A Cromwell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
689
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Szczesniak R, Andrinopoulou E, Li H, Jain R, Mayer-Hamblett N, Ostrenga J, et al.
J Cyst Fibros
. 2025 Feb;
PMID: 39929763
Background: Increased variability in forced expiratory volume in 1 s of % predicted (FEVpp) has been associated with accelerated lung function decline in individuals with cystic fibrosis (CF). Lung function...
2.
Ostrenga J, Robinson K, Brown A, Goss C, Cromwell E
J Cyst Fibros
. 2024 Nov;
24(1):183-186.
PMID: 39500648
We conducted a descriptive analysis of people with CF 40 years of age and older using CF Foundation Patient Registry data from 2022 to provide a current estimate of the...
3.
Hergenroeder G, Todd J, Ostrenga J, Goss C, Jain R, Morgan W, et al.
J Cyst Fibros
. 2024 Oct;
24(1):135-141.
PMID: 39472230
Background: This study aims to characterize the uptake of elexacaftor/tezacaftor/ivacaftor (ETI) following Food and Drug Administration (FDA) approval in October 2019. Methods: People with cystic fibrosis (PwCF) ≥12 years enrolled...
4.
Cromwell E, Ahn Y, Johnson P, Ramos K, Freeman A, Faro A, et al.
J Cyst Fibros
. 2024 Oct;
24(1):112-117.
PMID: 39358194
Background: The Cystic Fibrosis Foundation Patient Registry (CFFPR) maintains clinical data, including history of solid organ transplant, on people with cystic fibrosis (CF) who obtain care at CF Foundation-accredited care...
5.
Cromwell E, Ostrenga J, Sanders D, Morgan W, Castellani C, Szczesniak R, et al.
Eur Respir J
. 2024 Sep;
64(5).
PMID: 39227072
Background: Elexacaftor/tezacaftor/ivacaftor (ETI), which is approved for people with cystic fibrosis (pwCF) with a F508del variant, was further approved based on data in the USA for those carrying at least...
6.
Magaret A, Graham E, Caverly L, Cromwell E, Paynter A, Rosenfeld M, et al.
J Cyst Fibros
. 2024 Aug;
23(5):943-946.
PMID: 39147620
Clinical trials often demonstrate treatment efficacy through change in forced expiratory volume in one second (FEV), comparing single FEV measurements from post- versus pre-treatment timepoints. Day-to-day variation in measured FEV...
7.
Sanders D, Mayer-Hamblett N, Rosenfeld M, Polinieni D, Dasenbrook E, Szczesniak R, et al.
J Cyst Fibros
. 2024 Jul;
PMID: 39079877
Background: We characterized people with cystic fibrosis (CF) ineligible by genotype (not age) for currently approved CFTR modulator therapy using data from the US CF Foundation Patient Registry (CFFPR). Methods:...
8.
Schechter M, Ostrenga J, Cromwell E, Ren C, Fink A, Sanders D, et al.
Pediatr Pulmonol
. 2024 Jul;
59(12):3212-3220.
PMID: 38995116
Background: The benefit of antibiotic treatment of acute drops in FEV percent predicted (FEVpp) has been clearly established, but data from the early 2000s showed inconsistent treatment. Further, there is...
9.
Todd J, Morgan W, Szczesniak R, Ostrenga J, OConnell O, Cromwell E, et al.
Ann Am Thorac Soc
. 2024 Jun;
21(10):1416-1420.
PMID: 38889346
Declines in percent predicted forced expiratory volume in 1 second (ppFEV) are an important marker of clinical progression of cystic fibrosis (CF). We examined ppFEV variability in relation to a...
10.
Rosenfeld M, Cromwell E, Schechter M, Ren C, Flume P, Szczesniak R, et al.
J Cyst Fibros
. 2024 Mar;
23(3):443-449.
PMID: 38556415
Rationale: The American Thoracic Society recommended switching to race-neutral spirometry reference equations, as race is a social construct and to avoid normalizing disparities in lung function due to structural racism....